JAK1 and acute lymphoblastic leukemia: To directly assess the activity of JAK2 inhibitors, we treated the T-ALL PDX lines with ruxolitinib (a competitive inhibitor of the JAK1 and JAK2 kinases) alone, idasanutlin alone, or the combination.